San Jose, CA — Nerbio, a leader in intelligent patient monitoring solutions, proudly announces that its iTOF® device has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone marks iTOF as the world's first wireless, app-controlled quantitative neuromuscular blockade (NMB) monitoring device to achieve FDA clearance.
Memphis, TN — Nerbio, a fast-growing innovator in app-controlled patient monitoring technology, is proud to announce that it is establishing its U.S. sales operations in Memphis, Tennessee.
San Jose, CA — Nerbio, a global innovator in mobile-based anesthesia and critical care monitoring solutions, today released results from a multi-center case study highlighting the successful clinical adoption of its flagship device, the iTOF®, in over 1,700 surgical cases across India. The study confirms that iTOF—an FDA-cleared, app-controlled neuromuscular monitoring device—is not only clinically effective but highly accepted by anesthesia professionals, overcoming one of the key barriers to widespread adoption of quantitative monitoring in surgery.
Nerbio® and iTOF® are registered trademarks of
Nerbio Medical Software Platforms, Inc.
Copyright © 2025 Nerbio – All Rights Reserved